Author/Editor		Glaser, Marjan
Title		Naše izkušnje zdravljenja z interferonom alfa pri mlajših bolnikih z esencialno trombocitemijo
Translated title		Our experience with interferon alpha therapy in younger patients with essential thrombocytaemia
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 69, št. 1
Publication year		2000
Volume		str. 11-3
Language		slo
Abstract		Background. Essential thombocytemia (ET) is a chronic myeloproliferative disease with megakaryocyte cell line proliferation in bone marrow and excessive overproduction of morphologically and functionally abnormal platelets in blood. Two thirds of patients are symptomatic with various symptoms, which are of bleefing and thrombosis origin and can lead ro death. Current therapy is focused on prevention of this complications and several therapeutic agents are capable to lower the planet count in this patients. Patients and methods. We present 5 younger patients with different difficulties. As the only reason, ET was established and induction therapy with interferon alpha (IFN) was started and later continued as intermittent therapy from 4 till 8 years. Conclusions. IFN has been shown to have a therapeutic effect in patients with ET. The treatment with IFN is recommended especially in young people to avoid treatment with cytotoxic agents.
Summary		Izhodišča. Esencialna trombocitemija (ET) je kronična klonska mieloproliferativna bolezen, za katero je značilno razraščanje megakatiocitov v kostnem mozgu in zvečano število morfološko in funkcijsko nenormalnih trombocitov v krvi. Značilna je nagnjenost h krvavitvam ali trombozam. Med obolelimi so tudi mlajši bolniki. Bolezen zdravimo s citostatiki, interferonom alfa (INF) ali drugimi zdravili. Bolniki in metode. Predstavljemo 5 mlajših bolnikov z ET, ki smo jih zdravili z IFN. Vzdrževalno zdravljenej traja od 4 do 8 let. Zdravljenje z IFN je uspešen in varen način zmanjševanja števila trombocitov. Zdravljenje je priporočljivo predvsem pri mlajših bolnikih, da se izognemo zdravljenju s citostatiki.
Descriptors		THROMBOCYTHEMIA, HEMORRHAGIC INTERFERON-ALPHA ADULT MIDDLE AGE